9:41 AM
 | 
Sep 07, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed to significantly reduce disease activity as measured by the SLE Responder Index (SRI)-4 response at 12 months.

The double-blind, international trial enrolled 460 patients with moderately to severely active autoantibody-positive SLE who were receiving standard of care (SOC) to receive placebo or 150 or 300...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >